- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02532907
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood.
The introduction of new DAAs regimens that do not include IFN provides unique and novel opportunities to examine whether successful treatment-induced eradication of viral antigen results in reconstitution of T cell immunity. serum and liver tissue samples will be collected and stored in hopes of improving treatment and outcomes for future patients.
Panoramica dello studio
Descrizione dettagliata
This study is designed to obtain and store samples of serum and liver tissue in HCV-infected patients being treated with DAA therapy.
A liver biopsy will be performed pre-treatment for research reasons. A small liver sample that is not required for pathologic analysis will also be stored. Patients will undergo another liver biopsy at either 4 or 12 weeks after initiation of DAA therapy.
Any patients with HCV-related liver disease (age > 18) will be considered for this study.
Patients will have a 120 ml blood draw for research purposes at baseline and 12 weeks after stopping DAA treatment along with a 60 ml blood draw at 2, 4, 8, and 12 weeks of treatment.
The liver biopsy at baseline and then either at 4 or 12 weeks will be examined using molecular techniques to measure transcription of key genes involved in the antiviral response.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Sandra Boimbo
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria
- Signed informed consent
- Ages 18-70
- HCV-infected patients being treated with direct-acting antiviral (DAA) therapy.
Exclusion Criteria
- Pregnant women or females of childbearing potential that are not on contraception
- Institutionalized or mentally disabled persons
- Prisoners
- Unwilling or unable to provide informed consent
- Subjects who are HIV positive
- Anticipated inability to follow up
- Chronic anemia
- Platelet count < 100 for liver biopsy patients who have documented fatty liver disease by ultrasound prior to enrollment
- Any patient with bleeding disorders or prolonged INR
- Abstinent or consuming less than two drinks of alcohol per day.
- Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Patients who will have their second Liver biopsy at week 4
The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
|
patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point.
The liver biopsy is performed using standard protocol with ultrasound guidance.
|
Patients who will have their second Liver biopsy at week 12
Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
|
patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point.
The liver biopsy is performed using standard protocol with ultrasound guidance.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Changes in gene array from baseline to either 4 or 12 weeks after treatment.
Lasso di tempo: 1 year
|
To examine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood.
|
1 year
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Hugo Rosen, MD, University of Colorado, Denver
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 14-1794
- UL1TR001082 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Liver Biopsy
-
Weill Medical College of Cornell UniversityTerminato
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeReclutamentoFibrosi cistica | BiomarcatoriBelgio
-
Johns Hopkins UniversityAttivo, non reclutanteMalattia epatica allo stadio terminaleStati Uniti
-
The University of Texas Health Science Center,...Prevent Cancer FoundationCompletatoMalattia del fegato grasso non alcolicaStati Uniti
-
NeoDynamics ABReclutamento
-
Northwestern UniversityReclutamentoFragilità | Cirrosi | Trapianto di fegatoStati Uniti
-
University of VirginiaCompletato
-
Samsung Medical CenterSconosciuto
-
Academisch Medisch Centrum - Universiteit van Amsterdam...PerspectumNon ancora reclutamento
-
Modarres HospitalCompletatoComplicazione | Biopsia | ProstataIran (Repubblica Islamica del